Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269510 | 1.00 | MAPK9 (0.66) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL6367100 | 0.86 | MAPK9 (0.68) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL6367096 | 0.86 | MAPK9 (0.68) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL31062585 | 0.84 | AKR1C3 (0.66) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL7835310 | 0.84 | AKR1C3 (0.66) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL14537417 | 0.84 | AKR1C3 (0.66) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL21656188 | 0.82 | EDNRA (0.62) | MAPK9CYP1A2CYP2C19CYP2C9KMT2A | |
| SCHEMBL2183809 | 0.82 | MAPK9 (0.63) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 | |
| SCHEMBL6975784 | 0.81 | RAB9A (0.51) | MAPK9CYP1A2CYP2C19CYP2C9KMT2A | |
| SCHEMBL7975875 | 0.81 | MAPK9 (0.61) | MAPK9CYP1A2CYP2C19CYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| EP-0630366-B1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-0539343-B1 | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5378727-A | ADMINISTERING TO MAMMALS | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5254573-A | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0539343-A1 | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | MAPK9 3850/4885CYP1A2 409/4885CYP2C19 2854/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | MAPK9 3850/4885CYP1A2 409/4885CYP2C19 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.